Patients with sickle cell disease have an increased tendency to develop frequent and severe pyo-genic infections. Lymphocyte subpopulations were studied in 14 patients with homozygous sickle cell anaemia (SCA) using the OKT monoclonal antibody. The mean absolute lymphocyte counts observed in patients with SCA were similar to that of controls. The OKT8+ lymphocytes were significantly higher in SCA patients than in controls. The mean OKT3+ and OKT4+ lymphocytes were significantly lower in SCA patients than in controls, and there is a reversal of the normal OKT4+: OKT8+ ratio. The number of B cells present, as detected by surface membrane immunoglobulin, was significantly higher in SCA patients when compared with control values. These preliminary findings suggest an important mechanism to further explain the increased tendency to infection in SCA patients, in addition to the previously described immunological disorders and the asplenic state

Keywords:
Infection, Lymphocyte subsets, Monoclonal antibodies, Sickle cell anaemia
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.